|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.28 - 2.49|
|52 Week Range||1.00 - 4.44|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
What Happened The U.S. Food and Drug Administration announced March 15 an Advance Notice of Proposed Rulemaking (ANPRM) to procure information to help set the maximum nicotine level for cigarettes to non-addictive ...
Tobacco, not marijuana, is this company's main focus now. But the reason the stock isn't soaring is a little complicated.
While small-cap stocks, such as 22nd Century Group Inc (AMEX:XXII) with its market cap of US$311.38M, are popular for their explosive growth, investors should also be aware of their balanceRead More...
For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for 22nd Century Group, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)
The Clarence, New York-based company said it had a loss of 3 cents per share. The plant biotechnology company posted revenue of $4.5 million in the period. In the final minutes of trading on Thursday, ...
22nd Century Group Inc (AMEX:XXII) is a small-cap stock with a market capitalization of USD $270.56M. While investors primarily focus on the growth potential and competitive landscape of the small-capRead More...
22nd Century Group Inc (AMEX:XXII), a tobacco company based in United States, received a lot of attention from a substantial price movement on the AMEX in the over the lastRead More...
It's still the best-performing marijuana stock of the year, but a recent plunge puts its reign at the top in jeopardy.
If you're on the hunt for small-cap biotechs that could be big winners next year, Amarin, MannKind Corp., and 22nd Century Group need to be on your radar right now.
In a recent article, Tyler Stratford, director of client operations at Canna Advisors, one of the top cannabis consulting firms in North America, shared a few fundamental tips for obtaining a marijuana ...
Yahoo Finance's Seana Smith, Andy Serwer, Ethan Wolff-Mann and Dion Rabouin discuss why now could be a good time to invest in marijuana stocks.